The researchers found that a blood test measuring systemic levels of homocitrulline, a molecular marker for the pathway, serve as the strongest, independent predictor of heart disease risk identified thus far. It could help further define who is at risk for the development and progression of heart disease, and to help monitor the effectiveness of heart disease therapies.
"Our studies demonstrate that protein carbamylation is a fundamental and intrinsic process to atherosclerosis," Dr. Hazen said. "They establish a foundation for designing targeted therapies that may block this pathway to prevent the development and progression of heart disease."
About Cleveland Clinic's Lerner Research Institute
The Lerner Research Institute is home to Cleveland Clinic's laboratory- based and translational biomedical research. Its mission is to understand the causes of human diseases and to develop new treatments and cures. The Lerner Research Institute's total annual research expenditures exceed $120 million from Federal agencies, non-Federal societies and associations, endowment funds and the Cleveland Clinic. More than 1,100 people (including about 160 investigators, 350 junior faculty and postdoctoral fellows, and 120 graduate students) work in research programs focusing on cardiovascular, cancer, neurologic, musculoskeletal, allergic and immunologic, eye, metabolic, and infectious disease. The Institute also is an integral part of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University -- training the next generation of physician-scientists.
About Cleveland Clinic
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit
multispecialty academic medical center that integrates clinical and
hospital care with research and education. Cleveland Clinic was foun
|SOURCE Cleveland Clinic|
Copyright©2007 PR Newswire.
All rights reserved